With over a decade of extensive experience in the field of next-generation probiotics (NGPs), scientists at Creative Biolabs are proud to tailor the best-fit proposal to meet our customers' specific project requirements.
CD is an immune-mediated disorder initiated by the ingestion of gluten in genetically predisposed individuals. CD occurs in genetically predisposed individuals who develop an immune response to gluten. This disease is caused by an inappropriate immune response to wheat gluten, barley, and rye. This autoimmune disorder affects the small bowel and often produces symptoms of diarrhea, malabsorption, and extraintestinal symptoms. To date, the only therapy for CD is the mandatory and complete exclusion of dietary sources of grains and any food containing gluten, which is termed as a gluten-free diet (GFD). As novel therapies are being developed, complementary strategies are also being studied, such as modulation of the gut microbiome using probiotics.
Abnormalities in the gut microbiome in CD patients have led to the use of probiotics as a promising alternative. A possible role is documented for probiotics in improving CD-related symptoms, modulating the peripheral immune response, and altering the fecal microbiota. Also, probiotic combinations have a demonstrated ability to positively influence the gut microbiota composition or improve the defense system of the intestinal barrier. These probiotic-based therapies provide hope for enhanced, lifelong CD management with improved patient compliance and better quality of life. For many years, a variety of probiotics have been labeled ideal targets for the treatment and prevention of CD, including but not limited to:
Fig.1 Possible routes of probiotic in the maintenance of CD. (de Sousa Moraes, 2014)
These probiotics are effective in ameliorating the severity of CD symptoms. First, Bifidobacteria could exert immunoregulatory effects caused by an altered microbiota, protecting against the inflammatory response and mucosal damage caused by gliadin peptides. Similarly, a probiotic mixture with mainly Lactobacillus and Bifidobacterium species improved epithelial barrier functions by stabilizing tight junctions, which could decrease intestinal and systemic complications of the disease. Furthermore, Lactobacillus rhamnosus GG could restore the intestinal barrier function and protect the intestinal mucosa from gliadin peptide-induced damage. In addition, VSL#3 (containing 8 different bacteria), has been shown to reduce the toxicity of gluten when uses in a fermentation process. These studies, along with in vitro and animal studies, support the addition of probiotics to a GFD for beneficial or preventative effects in CD therapy.
As a global pioneer leader in the field of NGPs, Creative Biolabs is professional in offering probiotic drug discovery services to satisfy various project demands. To meet the growing demand for NGPs, Creative Biolabs has established one-stop solutions to generate a series of services for the discovery of NGPs. We could now offer comprehensive services including but not limited to probiotic drug development, qualification, and cGMP manufacturing services.
Equipped with advanced platforms and powerful technologies, Creative Biolabs is confident in offering the most suitable solution and achieve the best outcome for our customers. If there are any questions, please do not hesitate to contact us for more information.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.